German biotech firm Tubulis has raised €308 million in a record-breaking Sequence C funding spherical, marking the biggest Sequence C ever closed by a European biotech and the largest financing for a non-public antibody-drug conjugate (ADC) developer worldwide. The spherical was led by Venrock Healthcare Capital Companions, with participation from Wellington Administration and Ascenta Capital, alongside current traders together with Nextech Make investments, EQT Life Sciences, Frazier Life Sciences, Andera Companions, Deep Observe Capital, Bayern Kapital, Fund+, OCCIDENT, Seventure Companions, and HTGF.
Based in Munich, Tubulis specialises in growing uniquely matched ADCs that mix antibodies with potent medicine to focus on and destroy most cancers cells with excessive precision. The brand new funding will speed up the medical growth of its lead candidate, TUB-040, which targets NaPi2b, an antigen overexpressed in ovarian and lung cancers. At present underneath analysis in a Section I/IIa research, TUB-040 acquired Quick Observe designation from the U.S. FDA in 2024.
The recent capital may also advance Tubulis’ broader pipeline, together with TUB-030 and a number of preclinical programmes, in addition to broaden its proprietary ADC platform applied sciences. These improvements purpose to unlock new therapeutic prospects and enhance outcomes for sufferers with stable tumours.
“This landmark financing spherical displays the deep conviction these world healthcare traders have in Tubulis and the disruptive potential of our ADC platforms,” stated Dr. Dominik Schumacher, CEO and Co-founder of Tubulis. “With TUB-040 progressing within the clinic and first information to be shared in a late-breaking oral presentation at ESMO, we’re able to broaden into earlier therapy strains, whereas persevering with to innovate throughout our pipeline and expertise platforms. The brand new funding empowers us to execute on our imaginative and prescient of making really differentiated antibody-drug conjugates which can be tailor-made to the biology of stable tumours and might ship superior therapeutic worth to sufferers.”
HTGF (Excessive-Tech Gründerfonds), one in every of Tubulis’ earliest backers, renewed and expanded its dedication on this spherical. The investor co-led Tubulis’ Sequence A in 2020 and has supported the corporate from idea to medical growth, underlining Germany’s energy as a biotech innovation hub and its means to mobilise personal capital for capital-intensive applied sciences.
“HTGF was one in every of our earliest traders and supported us in shaping Tubulis throughout its youth. Their renewed dedication on this spherical displays the continued partnership and shared perception in our mission to broaden the therapeutic potential of ADCs for sufferers worldwide,” stated Dr. Dominik Schumacher, CEO and Co-founder of Tubulis.
Dr. Frank Hensel, Principal at HTGF, added: “Our relationship with Tubulis has at all times been constructed on belief and a shared ambition to redefine oncology therapy. This newest spherical, supported by main world traders, validates the energy of the platform and the staff. We’re proud to proceed backing Tubulis because it enters a pivotal section of medical growth.”
Dr. Achim Plum, Managing Director at HTGF, stated: “Tubulis’ Sequence C demonstrates that even extremely capital-intensive, disruptive applied sciences can entice the personal funding wanted to deliver cutting-edge therapies to sufferers. For us at HTGF, Tubulis is a first-rate instance of how we function: we have interaction very early, usually earlier than an organization is based, and construct trusted relationships with distinctive groups. This story displays our perception in scientific excellence, entrepreneurial imaginative and prescient, and the impression that may be achieved when each come collectively. Congratulations to your complete Tubulis staff on this excellent success.”
Tubulis’ breakthrough ADC applied sciences have positioned it as one in every of Europe’s most promising biotech gamers. By combining world-class science, medical progress, and world investor confidence, the corporate continues to advance its mission of increasing the therapeutic potential of ADCs for most cancers sufferers worldwide.
Elevate your perspective with NextTech Information, the place innovation meets perception.
Uncover the most recent breakthroughs, get unique updates, and join with a world community of future-focused thinkers.
Unlock tomorrow’s tendencies at this time: learn extra, subscribe to our e-newsletter, and turn out to be a part of the NextTech group at NextTech-news.com
